Enoki Mushrooms Recalled Nationwide for Potential Listeria Contamination—Here's What to Know
The mushrooms that were recalled were sold nationwide and packaged in green plastic. They were in a 200-gram package with a UPC Barcode 6 976532 310051 on the back label, distributed by Hofood99 Inc., 21903 56th Ave., Oakland Gardens, NY 11364.
Related: Are Food Recalls Really on the Rise? A Food Microbiologist Weighs In
So far, no illnesses have been reported in relation to the mushrooms, but Listeria monocytogenes is a common cause of food safety recalls. Listeria can cause high fevers, severe headache, stiffness, nausea, and diarrhea in healthy people—but infection with listeria can cause stillbirth or miscarriage in pregnant women, and deadly infections in young children, the elderly, and people with weakened immune systems.
Related: How to Wash Every Type of Mushroom So They're Safe to Eat
If you have the affected products, do not eat them. You can destroy the mushrooms or return them to the store for a full refund. If you have any questions, you can contact Hofood99 at 917-756-9833, between 9 a.m. and 2 p.m., Monday to Friday.
Read the original article on Real Simple
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Crinetics' treatment of CAH granted FDA orphan designation
Crinetics (CRNX)' treatment of congenital adrenal hyperplasia, generic name atumelnant, was granted FDA orphan designation, according to a post to the agency's site. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
an hour ago
- Business Insider
Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation
Keros Therapeutics (KROS)' treatment of Duchenne muscular dystrophy was granted FDA orphan designation, according to a post to the agency's site. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
3 hours ago
- Business Insider
Regenxbio announces FDA review extension for RGX-121 BLA
Regenxbio (RGNX) announced that the U.S. Food and Drug Administration extended its review timeline of the Biologics License Application for clemidsogene lanparvovec for the treatment of Mucopolysaccharidosis II, also known as Hunter syndrome. The Prescription Drug User Fee Act goal date has been extended from November 9, 2025 to February 8, 2026. The extension follows the company's submission of longer-term clinical data for all patients in the pivotal study of RGX-121 in response to an FDA information request. These positive 12-month clinical data are consistent with biomarker and neurodevelopmental data previously submitted on the same patients in the BLA and will be presented during the International Congress of Inborn Errors of Metabolism in September 2025. In August 2025, the FDA completed a pre-license inspection and bioresearch monitoring information inspection for the RGX-121 BLA with no observations. No safety-related concerns have been raised by the FDA during the BLA review. 'Boys with this rare, devastating disease have no treatment options to address neurodevelopmental decline, and the Hunter syndrome community is in urgent need for a therapeutic option with the potential to improve these patients' lives,' said Curran M. Simpson, President and Chief Executive Officer of REGENXBIO. 'We promptly provided the FDA with the information requested and expect the commercial launch plans remain on track.'
